驱动基因阴性的晚期非小细胞肺癌维持治疗进展  

Progress in maintenance therapy of driver gene-negative advanced non-small cell lung cancer

作　　者：袁菱玲 赵君慧[1] YUAN Lingling;ZHAO Junhui(Qinghai University,Qinghai Xining 810000,China)

机构地区：[1]青海大学,青海西宁810000

出　　处：《现代肿瘤医学》2022年第16期3037-3040,共4页Journal of Modern Oncology

基　　金：北京医卫健康公益基金会医学科学研究基金资助项目(编号:F1050B)。

摘　　要：肺癌是全球常见的致死率最高的恶性肿瘤。越来越多的研究表明,对于晚期非小细胞肺癌一线治疗后没有进展的患者,维持治疗使患者无进展生存期和总生存期明显获益。传统上对于没有检测到驱动基因的非小细胞肺癌患者,仅能接受化疗,其有效性低,且副作用大,寻找更加有效的治疗方案迫在眉睫。随着新药的层出不穷,本文对如何优化驱动基因阴性的晚期非小细胞肺癌患者的维持治疗,从而提高患者生存期作一综述。Lung cancer is a common malignancy with the highest mortality rate worldwide.An increasing number of studies have shown that maintenance therapy provides a significant benefit in progression-free survival and overall survival for patients who do not progress after first-line treatment for advanced non-small cell lung cancer.Traditionally,for patients with non-small cell lung cancer without detected driver genes,only chemotherapy can be received,which has low effectiveness and great side effects,and it is urgent to find more effective treatment options.With the emergence of new drugs,this article reviews how to optimize the maintenance treatment of patients with advanced non-small cell lung cancer with negative driver gene,so as to improve the survival time of patients.

关 键 词：晚期非小细胞肺癌(NSCLC) EGFR野生型 维持治疗 

分 类 号：R734.2[医药卫生—肿瘤]